ALERT Companion II Used in First U.S. Case.

Business Editors/Health/Medical Writers/High-Tech Writers

WEST BERLIN, N.J.--(BUSINESS WIRE)--Oct. 31, 2003

EP MedSystems, Inc. (Nasdaq: EPMD), a market leader in electrophysiology products used to diagnose and treat certain types of cardiac rhythm disorders, announced today that the ALERT(R) Companion II has been successfully used in its first routine internal cardioversion case in the United States.

Dr. James R. Higgins, a cardiologist practicing at Saint Francis Hospital in Tulsa, Oklahoma, has found the ALERT(R) Internal Cardioversion System to be a useful alternative to external biphasic cardioversion for patients in chronic atrial fibrillation (AF). "The ALERT system was utilized for a patient that had failed external biphasic cardioversion several times, and was anticipating either chronic AF or a lifelong regimen of antiarrhythmic drugs. Both situations are health risks for a patient. We used the ALERT(R) system, which easily cardioverted the patient back into normal sinus rhythm. The ALERT Internal Cardioversion is a new treatment option that gives the patient another chance to avoid chronic AF."

EPMD President & CEO Reinhard Schmidt stated, "Following thousands of successful outcomes in Europe over the last two years for treatment of both chronic AF and failed external cardioversion, we are looking forward to the introduction of this recently approved system to aid in the treatment of AF in critical care and chronic AF patient profiles in the United States. We are hopeful that this brings a profile of patients underserved by existing technologies a proven approved solution for the treatment of AF."

The ALERT(R) System delivers programmable low energy bi-phasic electrical impulses directly to the inside of a patient's heart to convert atrial fibrillation to a normal rhythm. The electrical impulses are delivered via the ALERT(R) catheter, a specially designed catheter used in tandem with an energy source called ALERT(R) Companion. Both the ALERT(R) catheter and ALERT(R) Companion, as a system, underwent a controlled, randomized clinical trial of over 150 patients demonstrating the products' safety and efficacy. The ALERT(R) System is covered by fourteen issued U.S. patents. Approximately 120 Companion II energy sources are presently in use in Europe.

EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac rhythm disorders. The Company's EP product line now includes the ViewMate(R) intracardiac ultrasound catheter system, the EP-WorkMate(R) Electrophysiology Workstation, the ALERT(R) internal cardioversion system, the EP-3(TM) Stimulator, diagnostic electrophysiology catheters, internal cardioversion catheters and related disposable supplies. EPMD's shareholders include Medtronic (NYSE: MDT), Boston Scientific (NYSE: BSX), EGS Private Healthcare Partnership, H & Q Lifesciences, and Cardiac Capital LLC. For more information, visit our Website at www.epmedsystems.com.

This Release contains certain statements of a forward-looking nature relating to future events or the future financial performance of EP MedSystems including, but not limited to financial forecasts for the year 2003. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of future profitability and future liquidity needs; and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual report filed on Form 10-KSB and quarterly reports filed on form 10-QSB.

EP MedSystems cautions investors and others to review the cautionary statements set forth in this Release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on the press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of anticipated events.